Jaume Capdevila Castillón

9PUBLICATIONS
99CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsBiological adaptationCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 04, 2026
Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.

Jaume Capdevila, Jorge Hernando, Javier Molina-Cerillo

|Sep 12, 2025
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).

Jaume Capdevila, Jorge Hernando, Javier Molina-Cerrillo

|Apr 08, 2025
Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes.

Carlota Arenillas, Lucía Celada, José Ruiz-Cantador

|Aug 08, 2024
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).

Maria Carmen Riesco-Martinez, Jaume Capdevila, Vicente Alonso

|Dec 05, 2023
A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.

Paul B Romesser, Jaume Capdevila, Rocio Garcia-Carbonero

|May 23, 2023
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.

J Capdevila, J Hernando, A Teule

Pageof 2

Frequent Collaborators

3 joint publications

Alex Teule

3 joint publications

Alejandro Garcia-Alvarez

3 joint publications

Paolo Nuciforo

3 joint publications

Rocio Garcia-Carbonero